Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

非酒精性脂肪性肝炎临床研究网络 (NASH CRN)

• 批准号: 10451687
• 负责人: NORAH A. TERRAULT
• 金额: $ 8.11万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10451687
• 关键词: Address; Adolescent; Adult; Affect; Amlodipine; Ancillary Study; Archives; Autophagocytosis; Biological Markers; Cardiovascular Diseases; Cardiovascular system; Child; Childhood; Cirrhosis; Clinical; Clinical Research; Clinical Trials; Collaborations; Complementary DNA; Coupled; DNA; Data; Data Coordinating Center; Databases; Diabetes Mellitus; Diagnosis; Disease; Disease Marker; Disease Progression; Double-Blind Method; Eating; Economic Burden; Enrollment; Epidemiology; Extrahepatic; Fatty Liver; Funding; Genetic; Goals; Health; Hepatic; High Prevalence; Human; Immunologics; Immunology; Incidence; Individual; Knowledge; Laboratory Study; Length; Life; Link; Lipids; Liver; Liver diseases; Longitudinal cohort; Longitudinal cohort study; Losartan; Malignant Neoplasms; Malignant neoplasm of liver; Measurement; Measures; Metabolic; Metabolic syndrome; Methods; Modeling; Modification; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; North America; Obesity; Outcome; Participant; Pathogenesis; Pathway interactions; Patients; Persons; Pharmaceutical Preparations; Phase; Placebo Control; Placebos; Plasma; Population; Population Study; Positioning Attribute; Prevalence; Prevention; Prevention strategy; Primary carcinoma of the liver cells; Prospective cohort; Publications; Randomized; Research; Resources; Risk; Risk Factors; Role; Safety; Sampling; Serum; Severity of illness; Stains; Testing; Therapeutic; Therapeutic Studies; Therapeutic Trials; Time; Tissues; Translational Research; United States; adverse outcome; base; biobank; biological specimen archives; burden of illness; chronic liver disease; clinical application; clinical center; clinical material; clinical research site; cohort; comorbidity; disease natural history; efficacy outcomes; experience; follow-up; liver biopsy; microbiome; mortality; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel marker; novel therapeutics; patient subsets; pediatric non-alcoholic fatty liver disease; pediatric patients; phase 2 study; prospective; recruit; success; tool; translational study; treatment strategy

Project Summary Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) ranks as one of the most important causes of chronic liver disease in the United States, with 1 of every 3 adults and 1 of every 5 children affected. NAFLD, especially NASH, is associated with increased liver, cardiovascular and cancer-related mortality. The NASH Clinical Research Network (NASH CRN) was established in 2002 to conduct research related to its clinical features, risk factors, pathogenesis, natural history and treatment in children and adults. Over the last funding cycle, the CRN has accrued a comprehensive database of 4,544 patients from five studies during the current funding period (to 1 Oct 18). Two clinical trials were completed (FLINT and CyNCh) and The Losartan for Pediatric NAFLD (STOP-NAFLD) trial is underway with first patient randomized in Oct 2018. Additionally, the NASH CRN has archived a total of 504,685 biospecimens (serum, plasma, liver tissue, DNA ad cDNA) in the NIDDK Biorepository, and 28,436 samples have been withdrawn for translational research using the Ancillary Studies mechanism. Since 2004, a total of 31 publications have resulted from the 104 approved Ancillary Studies. Building on the success of the last funding cycle, the NIDDK has issued RFA- DK-08-505 with the objectives of continue the NASH CRN for an additional 5 years. The objectives of the NASH CRN during this next funding period are: (a) to complete the network-wide studies initiated during the last funding period. These are two observational longitudinal cohort studies (the Adult and Pediatric NAFLD Database 2 studies) and a randomized double blind controlled therapeutic trial of losartan for NAFLD in children (STOP-CO, n=110). The NAFLD database may be amended to meet additional outcome goals during the next funding period. These modifications may include extending the length of follow-up of those enrolled, consideration of a follow-up liver biopsy in a subset of patients, and expansion to include greater focus on cardiovascular, diabetes and cancer-related outcomes; (b) to conduct new translational studies based on the clinical material and archived biospecimens from previous funding periods including novel markers of autophagy, an important means of controlling cellular lipids that is understudied relative to other lipid-regulating pathways in the liver and potential role in NAFLD disease severity; and (c) to conduct additional novel therapeutic studies in adults and children with NASH, such as the proposed phase 2 study of amlodipine, as pro-autophagic therapy, in children and adults with NASH (AMPAT Trial). Ancillary studies will leverage new collaborations (e.g. immunology, microbiome) to develop a comprehensive model of NAFLD/NASH which will allow identification of adults and children at risk and establish effective preventive and treatment strategies against NASH.

项目摘要 非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）是最常见的疾病之一。 在美国，慢性肝病的重要原因，每3个成年人中就有1个，每5个儿童中就有1个 影响。NAFLD，尤其是NASH，与肝脏、心血管和癌症相关的 mortality. NASH临床研究网络（NASH CRN）成立于2002年， 与儿童和成人的临床特征、危险因素、发病机制、自然史和治疗有关。 在上一个资助周期，CRN已经积累了一个综合数据库，其中包括来自五个国家的4，544名患者。 在目前的资助期间（至10月1日18）的研究。完成了两项临床试验（FLINT和CyNCh） 氯沙坦治疗儿童NAFLD（STOP-NAFLD）试验正在进行中，第一名患者于10月随机分组 2018.此外，NASH CRN共存档了504，685份生物标本（血清，血浆，肝组织， DNA和cDNA），并已抽取28，436份样品进行翻译 使用辅助研究机制进行研究。自2004年以来，共有31份出版物是由 104篇已批准的研究在上一个供资周期成功的基础上，NIDDK发布了RFA- DK-08-505，目标是将NASH CRN再延长5年。的目标 NASH CRN在下一个融资期内的目标是： (a)完成上一个资助期内启动的全网络研究。这是两个观察到的 纵向队列研究（成人和儿童NAFLD数据库2研究）和随机双盲 氯沙坦治疗儿童NAFLD的对照治疗试验（STOP-CO，n=110）。NAFLD数据库可能是 为满足下一个供资期的额外成果目标，对该计划进行了修订。这些修改可以包括 延长入组患者的随访时间，考虑在以下患者中进行随访肝活检： 患者，并扩展到更加关注心血管、糖尿病和癌症相关结果; (b)根据临床材料和存档的生物标本进行新的转化研究， 包括自噬的新标志物，这是控制细胞脂质的重要手段 相对于肝脏中的其他脂质调节途径以及在NAFLD疾病中的潜在作用， 严重性;以及 (c)在患有NASH的成人和儿童中进行额外的新型治疗研究，例如拟议的 在患有NASH的儿童和成人中进行的关于利多卡因作为促自噬疗法的2期研究（AMPAT试验）。 辅助研究将利用新的合作（例如免疫学，微生物组学）来开发一个全面的 NAFLD/NASH模型，该模型将允许识别处于风险中的成人和儿童，并建立有效的 针对NASH的预防和治疗策略。